down arrow

The Oncology Institute, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68236X1000
USD
3.23
0.27 (9.12%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Nutex Health, Inc.
Talkspace, Inc.
Precipio, Inc.
Aveanna Healthcare Holdings, Inc.
The Pennant Group, Inc.
The Joint Corp. (United States)
LifeMD, Inc.
The Oncology Institute, Inc.
Biodesix, Inc.
CareMax, Inc.
Invitae Corp.
Why is The Oncology Institute, Inc. ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate -287.44% of over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 1985.81%, its profits have risen by 7%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is The Oncology Institute, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
The Oncology Institute, Inc.
1574.44%
4.96
121.48%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
354.14%
EBIT Growth (5y)
-287.44%
EBIT to Interest (avg)
-18.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
8.08
Sales to Capital Employed (avg)
3.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.05%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
48.83
EV to EBIT
-5.54
EV to EBITDA
-6.34
EV to Capital Employed
6.27
EV to Sales
0.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-113.07%
ROE (Latest)
-1040.97%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -10.18 MM

NET SALES(Q)

Highest at USD 119.8 MM

RAW MATERIAL COST(Y)

Fallen by -13.4% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -810.94 %

PRE-TAX PROFIT(Q)

Highest at USD -13.1 MM

NET PROFIT(Q)

Highest at USD -9.95 MM

-7What is not working for the Company
INTEREST(HY)

At USD 7.44 MM has Grown at 81.33%

ROCE(HY)

Lowest at -535.24%

Here's what is working for The Oncology Institute, Inc.
Operating Cash Flow
Highest at USD -10.18 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 119.8 MM and Grown
In each period in the last five periods
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit
Highest at USD -13.1 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -9.95 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -810.94 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -13.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 1.8 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for The Oncology Institute, Inc.
Interest
At USD 7.44 MM has Grown at 81.33%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."